GTBIF Green Thumb Industries

$7.75
$0.05
(0.65%)
Today
Closed $7.75
$0.00
(0.00%)
After Hours
75

Extremely Bullish Sentiment

How do you feel about GTBIF?

Loading...
TSNDF Stock Rises 6.5% in a Month: Time to Buy, Hold or Sell?
TerrAscend's improving revenues, margins and cash flow support its recovery, while debt, competition and regulatory uncertainty remain key concerns.
Zacks
Wall Street Analysts See a 103.26% Upside in Green Thumb Industries Inc. (GTBIF): Can the Stock Really Move This High?
The consensus price target hints at a 103.3% upside potential for Green Thumb Industries Inc. (GTBIF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Cannabis Stock VRNO Rises 10% in a Month: Time to Buy, Hold or Sell?
Verano's rally follows strong Q2 results, but margin pressure and wider 2026 losses keep the stock in wait-and-watch mode.
Zacks
Can Green Thumb Industries Inc. (GTBIF) Run Higher on Rising Earnings Estimates?
Green Thumb Industries Inc. (GTBIF) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks
Wall Street Analysts Think Green Thumb Industries Inc. (GTBIF) Could Surge 104.86%: Read This Before Placing a Bet
The mean of analysts' price targets for Green Thumb Industries Inc. (GTBIF) points to a 104.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Should You Buy, Hold or Sell GTBIF Stock Post Q2 Earnings Release?
Green Thumb tops Q2 earnings and sales estimates, but can regulatory catalysts, buybacks and expansion plans outweigh pricing pressure and fierce competition?
Zacks
Should You Buy, Hold or Sell SNDL Stock Post Q4 Earnings Release?
SNDL sinks after weak Q2 2026 earnings, but can cost cuts and U.S. expansion through Parallel offset ongoing cannabis and liquor headwinds?
Zacks
Is JAZZ Still the Best Cannabis Stock After Federal Rescheduling?
Jazz Pharmaceuticals pairs its FDA-approved CBD blockbuster with a diversified drug portfolio, offering medical cannabis exposure despite ongoing pipeline risks.
Zacks
GTBIF Stock Climbs 17.5% in Three Months: Time to Invest or Cash Out?
Green Thumb has surged 17.5% in three months as regulatory progress, Q1 growth and buybacks lift sentiment, but competition and pricing pressure persist.
Zacks